CHEMEX CHX 108 ANTI-PSORIATIC WILL BEGIN CLINICALS WITHIN "ABOUT A MONTH,"
CHEMEX CHX 108 ANTI-PSORIATIC WILL BEGIN CLINICALS WITHIN "ABOUT A MONTH," becoming the company's third drug to reach the human test stage. Chemex announced at its annual meeting Sept. 22 in Denver that it has filed an IND for CHX 108. The new chemical entity "will be investigated for treatment of psoriasis and other inflammatory conditions of the skin," Chemex said. Already in clinicals for actinic keratosis are two antitumor drugs, CHX 100 and CHX 2053. CHX 100 is currently in Phase II. The Denver-based company has said that it expects to complete Phase III study of CHX 2053 and file an NDA for the compound by the end of 1988 ("The Pink Sheet" Aug. 24, T&G-4). Chemex also announced a drug evaluation and licensing agreement with Squibb at its annual meeting. "The agreement allows Chemex to evaluate certain drugs already under development or registered by Squibb to determine if these compounds might be of use in the treatment of skin diseases and disorders," the company said in a news release. If the Squibb compounds "show promise as possible dermatological products, Chemex has the right to develop and market these pharmaceuticals to dermatologists," the release stated. "The Squibb agreement is part of our company's business strategy to shorten the development time and accelerate market introduction of new skin care therapies," said Chemex President Edward Neiss, MD.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth